WO2002000274A1 - Reservoirs antimicrobiens destines a des dispositifs medicaux implantables - Google Patents

Reservoirs antimicrobiens destines a des dispositifs medicaux implantables Download PDF

Info

Publication number
WO2002000274A1
WO2002000274A1 PCT/US2001/020810 US0120810W WO0200274A1 WO 2002000274 A1 WO2002000274 A1 WO 2002000274A1 US 0120810 W US0120810 W US 0120810W WO 0200274 A1 WO0200274 A1 WO 0200274A1
Authority
WO
WIPO (PCT)
Prior art keywords
antimicrobial
reservoir
diffusable
medical device
supercritical
Prior art date
Application number
PCT/US2001/020810
Other languages
English (en)
Inventor
Joseph A. Chinn
C. P. Pathak
Original Assignee
Sulzer Carbomedics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulzer Carbomedics Inc. filed Critical Sulzer Carbomedics Inc.
Priority to JP2002505055A priority Critical patent/JP2004501683A/ja
Priority to CA002412492A priority patent/CA2412492A1/fr
Priority to EP01948834A priority patent/EP1303320A1/fr
Publication of WO2002000274A1 publication Critical patent/WO2002000274A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2409—Support rings therefor, e.g. for connecting valves to tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents

Definitions

  • This invention generally concerns medical devices intended for implantation into patients. More particularly, this invention relates to incorporation of antimicrobial substances in medical devices to inhibit infection on or near the medical device after its implantation.
  • Implantable medical devices have become critical in the management of a variety of human diseases and other conditions. Colonization by microorganisms on the surfaces of such medical devices following implantation occurs relatively infrequently but can produce serious and costly complications, including the need to remove and/or replace the implanted device, in conjunction with vigorous treatment of secondary infections.
  • PVE prosthetic valve endocarditis
  • planktonic bacteria microorganisms floating free in a cell culture
  • Planktonic bacteria behave differently than those adherent to a substrate, such as a bacterial culture vessel or an implanted medical device.
  • Planktonic bacteria are more susceptible to antimicrobial substances immobilized on a surface than are biofihn-producing bacteria.
  • devices coated with immobilized antimicrobial substances may effectively prevent colonization by planktonic bacteria in the laboratory but may be completely ineffective in preventing infection of devices in vivo by clinically relevant biofilm-producing bacteria.
  • planktonic bacteria cultured in the laboratory rather than biofilm bacteria derived from clinical infections, has led to the commercialization of numerous medical devices lacking clinical efficacy against the biofilm bacteria.
  • an antimicrobial substance should penetrate the biofilm.
  • the antimicrobial substance must be able to diffuse from the medical device into the surrounding tissue following implantation. Therefore, antimicrobial substances immobilized on the surface of a medical device (and thus not subject to diffusion) are largely ineffective against many clinically relevant microorganisms.
  • a more effective medical device would have the capacity to deliver diffusable antimicrobial substance(s) to the local environment following implantation.
  • U.S. Patent No. 5,624,704 discloses methods for impregnating a non-metallic medical implant with an antimicrobial substance by first dissolving the antimicrobial substance in an organic solvent to form an antimicrobial composition. Thereafter, a separate penetrating agent and alkalinizing agent is added to the antimicrobial composition. The resulting antimicrobial composition is then applied to a medical device of interest in order to incorporate the composition into the material of the medical device for post-implantation release.
  • Antimicrobial substances initially applied to an implantable medical device as a solute in an organic solvent would ideally remain incorporated in a predetermined distribution within the device as the solvent is removed. Maintenance of a desired predetermined antimicrobial substance distribution within such a device is important in obtaining predictable release kinetics for the antimicrobial substances in vivo (that is, after implantation). Such predictable release kinetics are, in turn, essential to establish a clinically efficacious antimicrobial zone of inhibition (ZOI) around the device for an effective time period while avoiding over-medication (that is, avoiding an excessive concentration of any antimicrobial substance around the device at any time).
  • ZOI clinically efficacious antimicrobial zone of inhibition
  • the present invention comprises methods and apparatus relating to implantable antimicrobial medical devices such as, by way of nonlimiting example, prosthetic heart valves, annuloplasty rings, pacemakers, pumps, and catheters.
  • Implantable antimicrobial medical devices comprise an implantable medical device which is coupled to at least one diffusable antimicrobial reservoir incorporating one or more antimicrobial substances in at least one porous, hydrophobic reservoir core.
  • a desired distribution of the antimicrobial substance is achieved by selectively loading portions of the corresponding reservoir(s) with one or more antimicrobial substances through use of a supercritical fluid solvent which comprises at least one supercritical or near-supercritical fluid which in turn preferably comprises supercritical carbon dioxide (SC02).
  • SC02 supercritical carbon dioxide
  • the antimicrobial substances are present in a predetermined, non-uniform distribution in the reservoir core.
  • the distribution of antimicrobial substance(s) in a diffusable antimicrobial reservoir according to the present invention results in timed release of sufficient amounts of the substance(s) to maintain a medically effective ZOI around the implantable antimicrobial medical device in vivo for a clinically effective period of time.
  • Initially establishing the ZOI will generally require a relatively higher rate of antimicrobial diffusion from the reservoir to raise antimicrobial tissue concentrations to effective levels and/or to counteract infectious agent contamination during implantation.
  • one or more antimicrobial substances are released from the reservoir sufficiently rapidly to maintain a clinically effective ZOI without over-medication.
  • SC02 is a powerful solvent for lipids, oils and other small molecular weight organic compounds. It is insoluble in water, and its solvating power can be controlled by changes in temperature and/or pressure as disclosed in the above references and, e.g., in U.S. Patent No. 5,533,538, incorporated herein by reference in its entirety.
  • SCO2 is commercially used to extract flavors and oils directly from seeds and other agricultural feed materials. Issued patents also disclose its utility in forming fine particles of physiologically active substances (see, e.g., U.S. Patent No. 5,639,441, incorporated herein by reference), and delivering such particles directly to a human or animal (see, e.g., U.S. Patent No. 5,301,664, incorporated herein by reference). None of the foregoing references, however, disclose the use of SC02 or other supercritical fluid in making diffusable antimicrobial reservoirs as in the present invention.
  • SC02 is often used in combination with one or more adjuvants such as cosolvents (e.g., nitrous oxide or ethanol), and/or surfactants (e.g., polysorbate 80 or dipalmitoyl lecithin), as noted in the above references.
  • cosolvents e.g., nitrous oxide or ethanol
  • surfactants e.g., polysorbate 80 or dipalmitoyl lecithin
  • Carbon dioxide itself is relatively benign environmentally, so solvent disposal costs are reduced through its use.
  • the solvating power of supercritical fluid solvents preferably comprising SC02 is controlled to cause precipitation of selected antimicrobial substances carried by such solvents in predetermined distributions within antimicrobial reservoirs. Note that where more than one antimicrobial substance of the present invention is carried by a supercritical fluid solvent, selective precipitation of each such antimicrobial substance may be obtained through control of solvent temperature and solvent ambient pressure.
  • Selective precipitation of antimicrobial substance(s) from a supercritical fluid solvent may be effected, for example, by either heating or cooling such solvents (depending on the solutes carried), and/or by decreasing solvent ambient pressure sufficiently to cause reversion of a solvent component to a subcritical state.
  • SCO2 and a supercritical cosolvent such as nitrous oxide
  • Preheated or precooled portions of antimicrobial reservoirs may thus be made to preferentially incorporate selected antimicrobial substances.
  • heating or cooling may be applied selectively to precipitate antimicrobial substance(s) from a supercritical fluid solvent already present at preferred locations within an antimicrobial reservoir.
  • selective loading of preferred portions of antimicrobial reservoirs with antimicrobial substances can be achieved through reduction of solvent ambient pressure which causes precipitation of solute loads substantially in place (that is, without substantial solute redistribution).
  • Establishment of a dynamic solvent ambient pressure gradient within an antimicrobial reservoir core can facilitate precipitation of antimicrobial substance(s) at one or more preferred locations within the core.
  • Implantable antimicrobial medical devices of the present invention comprise one or more diffusable antimicrobial reservoirs coupled to an implantable medical device, each such reservoir comprising at least one porous, hydrophobic reservoir core which itself comprises, for example, polyester fabric and/or polytetrafluoroethylene (PTFE)/silicone rubber felt.
  • PTFE polytetrafluoroethylene
  • Coupling of a diffusable antimicrobial reservoir to a medical device is achieved by direct coupling of the corresponding reservoir core(s) to the medical device or, alternatively, by coupling to the medical device a permeable reservoir core covering which itself is coupled to the corresponding reservoir core(s).
  • the antimicrobial reservoirs are incorporated into the sewing cuff of a prosthetic heart valve, and in the interior of annuloplasty rings. Coupling of such a reservoir core or a permeable cover thereof to a medical device may be accomplished by, for example, bonding, sewing, clamping, fusing, clipping, and analogous techniques known to those skilled in the art. Preferred coupling techniques will depend in part on the mechanical strength required of the coupling and the inherent mechanical strength of each reservoir core and/or any permeable covering thereof that may be present.
  • Each porous, hydrophobic core of an antimicrobial reservoir incorporates (as, for example, by adsorption and/or mechanical trapping of crystallized antimicrobial substances) one or more diffusable antimicrobial substances.
  • Each such substance is subject to controlled release in vivo as a solute in biological fluid which penetrates the reservoir core and which also communicates with biological fluid adjacent to the implanted device.
  • Time periods during which a diffusable antimicrobial substance is released from an antimicrobial reservoir of the present invention are predetermined, in part, by choice of the porosity of each corresponding hydrophobic core, as well as the molecular weight, polarity, distribution and concentration of diffusable substance(s) incorporated within the reservoir.
  • Preferred choices for diffusable antimicrobial substances include, but are not limited to, silver sulfadiazine, silver nitrate, rifampin, minocycline, or chlorhexidene diacetate.
  • Other factors which may determine the release kinetics of such antimicrobial substances to obtain an effective ZOI in vivo include the nature of the tissue and/or biological fluids through which diffusion takes place, as well as the flow rates of the relevant biological fluids.
  • An implantable device such as a heart valve, which is intended to contact both biological fluids and substantially solid tissue, may preferably comprise two or more different diffusable antimicrobial reservoirs. Incorporating different diffusable antimicrobial substances having (optionally) different diffusion rates in multiple diffusable antimicrobial reservoirs may serve, in selected applications, to more effectively inhibit microbial activity in the respective tissue(s) and fluid(s) contacting an implanted antimicrobial medical device.
  • microbial inhibition can be more accurately tailored to type, location, and order of appearance of clinically important infectious agent potentially affecting an implanted device within the period of early- onset infection (generally within 60 days of implantation).
  • One such preferred method comprises, in part, dissolving one or more antimicrobial substances in a suitable supercritical fluid solvent, optionally comprising one or more cosolvents or surfactants or combinations thereof, to form a supercritical antimicrobial solution.
  • the supercritical antimicrobial solution is thereafter incorporated into one or more porous, hydrophobic reservoir cores where one or more antimicrobial substances are precipitated in a predetermined distribution.
  • Such precipitation is effected through application of heating, cooling or reduction in ambient pressure on the supercritical antimicrobial solution. Subsequent removal of any supercritical solvent component(s) where heating or cooling alone has been used to effect such precipitation, or of any subcritical solvent component(s) where reduction in ambient pressure has been used to effect such precipitation, yields an antimicrobial reservoir.
  • a supercritical antimicrobial solution confers several advantages on the above methods.
  • the viscosity of such a solution is relatively low, thereby facilitating rapid penetration of porous, hydrophobic reservoir cores by the solution.
  • a desired (predetermined) distribution of precipitated antimicrobial substance solutes in a reservoir core may be obtained through selective heating or cooling of the solution and/or through general reduction of ambient pressure.
  • the portion of any supercritical antimicrobial solution consisting of carbon dioxide is relatively easy to recover and also relatively benign environmentally, thus reducing processing costs.
  • Disadvantages of using supercritical fluid solvents include the relatively high cost of equipment used to achieve and maintain temperatures and pressures compatible with the corresponding supercritical fluid states of solvent components. Energy costs associated with cycling between subcritical and supercritical states may also be significant. These costs can be reduced, however, if precipitation of antimicrobial substances from a supercritical antimicrobial solution is preferably achieved through heating or cooling the solution in a supercritical state, rather than through reducing ambient pressure to convert a supercritical fluid solvent component to a subcritical state.
  • an antimicrobial reservoir comprises a polytetrafluoroethylene felt reservoir core incorporating an antimicrobial substance and covered by permeable polyester fabric. Permeable cover is clamped to prosthetic heart valve by retainer rings, thus coupling reservoir to prosthetic heart valve.
  • incorporación of the antimicrobial substance into or onto the antimicrobial reservoir core is in a predetermined advantageous distribution.
  • the antimicrobial substance thus incorporated into an implantable antimicrobial medical device according to the present invention exhibits clinically desirable antimicrobial release kinetics from the medical device after exposure to an in vivo environment. Consequently, such medical devices are less susceptible to microbial colonization following implantation.
  • Phrases such as "incorporated into” and “incorporating into” as used herein mean that at least some diffusable antimicrobial substance permeates, adheres to, resides within, or otherwise becomes associated with one or more of the porous, hydrophobic structures (reservoir cores) of which the antimicrobial reservoir is comprised.
  • diffusable antimicrobial substance may be largely associated with the surface of a core (as in a coating), may penetrate within or between the pores of the core, may be covalently or ionically bound to the core structure, etc.
  • the preferred nature of the association between diffusable antimicrobial substance(s) and antimicrobial reservoir core(s) of the present invention depends on the particular diffusable antimicrobial substance used, the antimicrobial activity (including, for example, release kinetics) desired in the implanted antimicrobial medical device, and/or the type and structure of the medical device itself.
  • the diffusable fraction of antimicrobial substance(s) incorporated into or onto the antimicrobial reservoir core of an implantable antimicrobial medical device may be evaluated by, for example, mass analysis of the core or of the entire device before and after treatment.
  • the incorporated antimicrobial substance remaining after treatment may be extracted or otherwise removed from the device using an appropriate method, to be compared with the amount initially incorporated.
  • An implantable antimicrobial medical device made and/or used in accordance with the present invention may be selected from any of the numerous device types available to the medical practitioner, including cardiovascular devices, orthopedic implants, and a variety of other prosthetic devices.
  • Examples of such devices may include, but are not limited to, annuloplasty rings, heart valve sewing cuffs, catheter sewing cuffs, pericardial patches, vascular grafts, wound dressings, sutures, pledgets, and other like devices. Additional examples may include fixator pins, femoral prostheses, acetabular prostheses, dental prostheses and the like.
  • Antimicrobial substance refers to essentially any antibiotic, antiseptic, disinfectant, etc., or combination thereof, effective for inhibiting the viability and/or proliferation of one or more microorganisms. Numerous classes of antibiotics are known and may be suitable for use in accordance with this invention.
  • antibiotics may include, but are not necessarily limited to, tetracyclines (e.g., minocycline), rifamycins (e.g., rifampin), macrolides (e.g., erythromycin), penicillins (e.g., nafcillin), cephalosporins (e.g., cefazolin), other beta-lactam antibiotics (e.g., imipenem and aztreonam), aminoglycosides (e.g., gentamicin), chloramphenicol, sulfonamides (e.g., sulfamethoxyazole), glycopeptides (e.g., vancomycin), quinolones (e.g., ciprofloxacin), fusidic acid, trimethoprim, metronidazole, clindamycin, mupirocin, polyenes (e.g., amphotericin B), azotes (
  • antibiotic substances examples include minocycline, rifampin, erythromycin, nafcillin, cefazolin, imipenem, aztreonam, gentamycin, sulfamethoxazole, vanomycin, ciprofloxacin, trimethoprim, metronidazole, clindamycin, telcoplanin, mupirocin, azithromycin, clarithromycin, ofloxacin, lomefloxacin, norfloxacin, nalidixic acid, sparfloxacin, pefloxacin, amifloxacin, enoxacin, fleroxacin, ternafloxacin, tosufloxacin, clinafloxacin, sulbactam, clavulanic acid, amphotericin B, fluconazole, itraconazole, ketoconazole, nystatin, and
  • the antibiotics used in accordance with this invention will generally be selected so as to have relatively low water solubility such that their period of dissolution into biological fluids is prolonged. Moreover, it may be desired for many applications that one or more antimicrobial substances having distinct modes of action are incorporated into an antimicrobial reservoir in order to achieve a broader range of antimicrobial activity.
  • Suitable antiseptics and disinfectants for use in this invention may include, for example, hexachlorophene, cationic bisiguanides (e.g., chlorohexidine, cyclohexidiene, etc.), iodine and iodophores (e.g., povidone-iodine), para-chloro-meta-xylenol, furan medical preparations (e.g., nitrofurantoin, nitrofurazone), methenamine, aldehydes (glutaraldehyde, formaldehyde, etc.), alcohols, and the like.
  • hexachlorophene e.g., cationic bisiguanides (e.g., chlorohexidine, cyclohexidiene, etc.), iodine and iodophores (e.g., povidone-iodine), para-chloro-meta-xylenol, fur
  • the antimicrobial substances incorporated in an antimicrobial reservoir according to this invention comprise minocycline or rifampin or a mixture thereof.
  • Minocycline is a semisynthetic antibiotic derived from tetracycline that functions by inhibiting protein synthesis.
  • Rifampin is a semisynthetic derivative of rifamycin B, a macrocyclic antibiotic compound produced by the mold, Streptomyces mediterranic. Rifampin inhibits bacterial DNA-dependent RNA polymerase activity and is bactericidal in nature.
  • Both minocycline and rifampin are commercially available, are soluble in numerous organic solvents, and are active against a wide range of gram-positive and gram-negative organisms.
  • the desired antimicrobial substance(s) is first dissolved in an appropriate supercritical fluid solvent to form a supercritical antimicrobial solution.
  • Preferred supercritical fluid solvents include those comprising SC02 that will effectively dissolve the antimicrobial substance(s) of interest and that will facilitate incorporation of at least some of the dissolved antimicrobial substance(s) into an antimicrobial reservoir core in a predetermined distribution.
  • Cosolvents and/or surfactants may optionally be added to SCO2 to achieve desired characteristics.
  • a supercritical fluid solvent of the present invention is preferably selected from those that will readily spread onto and/or into the particular antimicrobial reservoir core surface(s) to which it is applied.
  • the degree of this spreading may be influenced by surface tension effects of solvent components and by the surface characteristics and configuration of the material(s) of the antimicrobial reservoir core(s).
  • CI to C6 organic solvents such as CI to C6 alcohols (e.g., methanol, ethanol, etc.), CI to C6 ethers (e.g., tetrahydrofuran), CI to C6 aldehydes, aprotic heterocyclics (e.g., n-methyl pyrrolidinone, dimethyl sulfoxide, dimethyl formamide), acetonitrile, and acetic acid.
  • concentration of the antibiotic substance(s) in the supercritical antibiotic solution is not specifically restricted. Optimal concentration ranges will likely vary depending upon the particular antimicrobial substance(s) and solvent(s) used, on the conditions under which the supercritical antimicrobial solution is contacted with the antimicrobial reservoir, and on the porosity and degree of hydrophobicity of the antimicrobial reservoir core. They can, nonetheless, be readily determined by an individual skilled in the art. In general, a higher concentration of a antimicrobial substance in the supercritical antimicrobial solution will result in greater incorporation into or onto the antimicrobial reservoir core under an otherwise constant set of application conditions. However, an upper concentration limit will typically characterize a particular combination of supercritical antimicrobial solution and antimicrobial reservoir core, above which further antimicrobial incorporation will become limited.
  • the concentration of the antimicrobial substance in the supercritical antimicrobial solution is essentially in the range of about 1 mg/ml to 60 mg/ml for each antimicrobial substance present.
  • the supercritical antimicrobial solution of the present invention is applied to, or otherwise contacted with, at least some portion of the antimicrobial reservoir core of interest in order to effect incorporation of the antimicrobial substance(s) into the reservoir core.
  • the means by which the antimicrobial solution is contacted with the medical device is not critical, and may vary depending on the type of reservoir core, its size and configuration, etc. Typically, the antimicrobial reservoirs will simply be immersed in a supercritical antimicrobial solution.
  • the supercritical antimicrobial solution may be applied to the reservoir, e.g., by injection, flushing, spraying, etc.
  • Other techniques for contacting the supercritical antimicrobial solution with the antimicrobial reservoir will be readily apparent to those skilled in the art.
  • the antimicrobial solution is generally allowed to remain in contact for a duration and under conditions of temperature, pressure, etc. effective to cause a desired degree of incorporation of the antimicrobial substance into or onto the reservoir core(s).
  • the optimal contact may vary depending on a number of parameters, e.g., the specific supercritical antimicrobial solution being used, contact temperature, etc., all of which can be readily determined by one skilled in the art.
  • Antimicrobial reservoirs of the present invention are typically dried (after precipitation of antimicrobial substances from a supercritical antimicrobial solution in a desired predetermined distribution) to eliminate any residual solvent component from the reservoir core(s).
  • drying e.g., by air-drying, heating, vacuum drying, etc,
  • the antimicrobial substance(s) incorporated into or onto a reservoir core is not subject to substantial diffusion until implanted in vivo, or otherwise exposed to a comparable environment. Wherever the incorporated antimicrobial substance(s) becomes redissolved, it therefore becomes subject to diffusion from the reservoir into the surrounding (fluid) environment.
  • Implantable antimicrobial medical devices of the present invention may include essentially any implantable medical device coupled to one or more antimicrobial reservoirs wherein effective incorporation of an antibiotic substance can be achieved.
  • implantable medical devices comprised of thermoplastic or polymeric materials such as rubber, plastic, polyethylene, polyurethane, silicone, PTFE, polyethylene terepthalate, latex, elastomers, and other like materials.
  • medical devices comprised of thermoplastic or polymeric materials such as rubber, plastic, polyethylene, polyurethane, silicone, PTFE, polyethylene terepthalate, latex, elastomers, and other like materials.
  • These may also include metals (e.g., titanium, cobalt-chromium, stainless steel) and ceramics (hydroxyapetite, pyrolytic carbon) in cancellous, i.e., porous, configurations.
  • Such medical devices contain at least some materials in a fabric or fabric-like form which may overlay, contain, and give shape to an antimicrobial reservoir core, as well as coupling the core to the corresponding medical device.
  • Such fabric and fabric-like materials preferably comprise polymeric fibers comprised of PTFE, polyethylene terepthalate, and other like materials. Examples of such devices which contain at least some of these materials may include, but are not limited to, annuloplasty rings, heart valve sewing cuffs, catheter sewing cuffs, pericardial patches, vascular grafts, wound dressings, sutures, pledgets, etc.
  • an implantable antimicrobial medical device is implanted which exhibits diffusion of one or more antimicrobial substances from the device for some period of time after the device has been exposed to an in vivo environment.
  • the release kinetics of the antimicrobial substance(s) from the device may be evaluated using any one of a variety of approaches. For example, one may sequentially monitor over time the diffusion of antimicrobial substance from the device into a solution in which the device is immersed. The solution may be replaced at certain time points, and the quantity of antimicrobial substance evaluated at the various time points by a suitable analytic technique, such as high-performance liquid chromatography.
  • Zone of inhibition (ZOI) analyses and variations thereof may also be used (see, for example, Sheretz, et al. Antimicrobial Agents and Chemotherapy, Aug. 1989, p. 1174, 1989).
  • an implantable antimicrobial medical device is placed directly on an agar plate covered with growing bacteria. The plates are evaluated over time to determine the extent of bacterial growth in the agar surrounding the device.
  • a bacterial free zone (called a zone of inhibition) surrounding, for example, the sewing cuff of an antimicrobial prosthetic heart valve as described herein, is indicative of inhibition of bacterial growth by substance(s) diffusing from the cuff into the surrounding agar.
  • the antimicrobial release kinetics and/or activity from an antimicrobial reservoir is generally sustained for an extended number of days, or even weeks. In this way, a patient's susceptibility to post-operative infection may be reduced for a clinically relevant duration following device implantation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)

Abstract

L'invention concerne des dispositifs médicaux antimicrobiens implantables comprenant un ou plusieurs noyaux hydrophobes, poreux contenant des substances antimicrobiennes dans des distributions prédéfinies pour une libération lente in vivo. Ces distributions prédéfinies de substances antimicrobiennes introduites dans des noyaux de réservoir antimicrobien sont effectuées par utilisation de supports de solvant fluide supercritique. La précipitation de substances antimicrobiennes de tels supports de solvant dans des distributions prédéfinies est accomplie par chauffage, refroidissement ou application de pression ambiante diminuée aux supports de solvant.
PCT/US2001/020810 2000-06-28 2001-06-28 Reservoirs antimicrobiens destines a des dispositifs medicaux implantables WO2002000274A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2002505055A JP2004501683A (ja) 2000-06-28 2001-06-28 埋込可能医療装置用抗菌物質レザバー
CA002412492A CA2412492A1 (fr) 2000-06-28 2001-06-28 Reservoirs antimicrobiens destines a des dispositifs medicaux implantables
EP01948834A EP1303320A1 (fr) 2000-06-28 2001-06-28 Reservoirs antimicrobiens destines a des dispositifs medicaux implantables

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60580400A 2000-06-28 2000-06-28
US09/605,804 2000-06-28

Publications (1)

Publication Number Publication Date
WO2002000274A1 true WO2002000274A1 (fr) 2002-01-03

Family

ID=24425286

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/020810 WO2002000274A1 (fr) 2000-06-28 2001-06-28 Reservoirs antimicrobiens destines a des dispositifs medicaux implantables

Country Status (4)

Country Link
EP (1) EP1303320A1 (fr)
JP (1) JP2004501683A (fr)
CA (1) CA2412492A1 (fr)
WO (1) WO2002000274A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2387115A (en) * 2002-04-04 2003-10-08 Univ London Endoprosthetic implant
US7919112B2 (en) 2004-08-26 2011-04-05 Pathak Holdings, Llc Implantable tissue compositions and method
US8192481B2 (en) 2004-06-22 2012-06-05 Boston Scientific Scimed, Inc. Implantable medical devices with anti-microbial and biodegradable matrices
US20180318468A1 (en) * 2015-11-12 2018-11-08 The Gereral Hospital Corporation Methods of making therapeutic polymeric material
US11850329B2 (en) 2009-02-20 2023-12-26 The General Hospital Corporation Methods of making a layered consolidated UHMWPE for use as a medical implant, and products made by the methods
US11970600B2 (en) 2021-03-31 2024-04-30 The General Hospital Corporation Di-cumyl peroxide crosslinking of UHMWPE

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0421164D0 (en) 2004-09-23 2004-10-27 Univ Nottingham Medical devices and methods of making medical devices
EP2475405B1 (fr) 2009-09-09 2016-04-13 Cook Medical Technologies LLC Modification de surface de substrat en utilisant un fluide densifié et un modificateur de surface
CN105353062A (zh) * 2015-11-25 2016-02-24 北京化工大学 一种测定米诺环素及其有关物质的hplc分析方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004682A1 (fr) * 1987-11-23 1989-06-01 Colorado Biomedical Incorporated Procede et dispositif anti-microbiens
EP0405284A2 (fr) * 1989-06-29 1991-01-02 Hercules Incorporated Cathéters imprégnés d'un produit pharmaceutique
DE4202320A1 (de) * 1992-01-29 1993-08-05 Dierk Dr Knittel Verfahren zum impraegnieren von substraten
US5340614A (en) * 1993-02-11 1994-08-23 Minnesota Mining And Manufacturing Company Methods of polymer impregnation
EP0879595A2 (fr) * 1997-04-30 1998-11-25 Schneider (Usa) Inc. Couches délivrant des agents médicinaux pour dispositifs médicaux
US20010003007A1 (en) * 1999-01-19 2001-06-07 Chinn Joseph Andrew Antibiotic treated implantable medical devices

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004682A1 (fr) * 1987-11-23 1989-06-01 Colorado Biomedical Incorporated Procede et dispositif anti-microbiens
EP0405284A2 (fr) * 1989-06-29 1991-01-02 Hercules Incorporated Cathéters imprégnés d'un produit pharmaceutique
DE4202320A1 (de) * 1992-01-29 1993-08-05 Dierk Dr Knittel Verfahren zum impraegnieren von substraten
US5340614A (en) * 1993-02-11 1994-08-23 Minnesota Mining And Manufacturing Company Methods of polymer impregnation
EP0879595A2 (fr) * 1997-04-30 1998-11-25 Schneider (Usa) Inc. Couches délivrant des agents médicinaux pour dispositifs médicaux
US20010003007A1 (en) * 1999-01-19 2001-06-07 Chinn Joseph Andrew Antibiotic treated implantable medical devices

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2387115A (en) * 2002-04-04 2003-10-08 Univ London Endoprosthetic implant
US8192481B2 (en) 2004-06-22 2012-06-05 Boston Scientific Scimed, Inc. Implantable medical devices with anti-microbial and biodegradable matrices
US7919112B2 (en) 2004-08-26 2011-04-05 Pathak Holdings, Llc Implantable tissue compositions and method
US11850329B2 (en) 2009-02-20 2023-12-26 The General Hospital Corporation Methods of making a layered consolidated UHMWPE for use as a medical implant, and products made by the methods
US20180318468A1 (en) * 2015-11-12 2018-11-08 The Gereral Hospital Corporation Methods of making therapeutic polymeric material
US11970600B2 (en) 2021-03-31 2024-04-30 The General Hospital Corporation Di-cumyl peroxide crosslinking of UHMWPE

Also Published As

Publication number Publication date
EP1303320A1 (fr) 2003-04-23
CA2412492A1 (fr) 2002-01-03
JP2004501683A (ja) 2004-01-22

Similar Documents

Publication Publication Date Title
US6528107B2 (en) Method for producing antimicrobial antithrombogenic medical devices
US7081133B2 (en) Antibiotic treated implantable medical devices
US6416548B2 (en) Antimicrobial annuloplasty ring having a biodegradable insert
AU635197B2 (en) Antimicrobial device and method
ES2248809T3 (es) Cateteres e implantes medicos impregnados con un agente antimicrobiano y metodo para impregnar los mismos.
AU2002320366B2 (en) Method for treating medical devices using glycerol and an antimicrobial agent
US20170354813A1 (en) Medical devices and methods of making medical devices
US7314857B2 (en) Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
US5772640A (en) Triclosan-containing medical devices
ES2327492T3 (es) Dispositivos medicos antimicrobianos.
WO2005096990A2 (fr) Nouvelle modification de protheses medicales
US20100069854A1 (en) Elastomeric Devices Containing Chlorhexidine/Fatty Acid Salts Made From Fatty Acids of 12 to 18 Carbons
AU2002320366A1 (en) Method for treating medical devices using glycerol and an antimicrobial agent
JPH0924093A (ja) 移植体、その手術中の用途及びその製造方法
EP1303320A1 (fr) Reservoirs antimicrobiens destines a des dispositifs medicaux implantables
Quinlan et al. The release of antibiotics from bone cement

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001948834

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2412492

Country of ref document: CA

WWW Wipo information: withdrawn in national office

Ref document number: 2001948834

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001948834

Country of ref document: EP